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Comparison of case subjects hospitalized with laboratory proven H1N1 versus matched case 

























Age at Hospitalization*   0.507 
> 2 years 35 (77.8) 80 (82.5)  
≤ 2 years 10 (22.2) 17 (17.5)  
Gender   0.301 
Female 26 (57.8) 47 (48.5)  
Male 19 (46.2) 50 (51.5)  
Race/Ethnicity┴*   0.002 
Hispanic 14 (31.1) 16 (16.5)  
Black/other non-white 12 (26.7) 9 (9.3)  
White 19 (42.2) 72 (74.2)  
Breastfed (self-reported)   0.124 
Yes 23 (52.3) 62 (66.0)  
No 21 (47.7) 32 (34.0)  
Caregiver education   0.049 
College graduate 16 (40.0) 55 (58.5)  
Some college or less 24 (60.0) 39 (41.5)  
Household income   0.021 
> $30K 14 (41.2) 54 (64.3)  
< $30K 20 (58.8) 30 (35.7)  
Preterm   0.565 
Yes 8 (18.6) 14 (14.7)  
No 35 (81.4) 81 (85.7)  
School/daycare attendance   0.467 
Yes 33 (75.0) 78 (80.4)  
No 11 (25.0) 19 (19.6)  
Respiratory comorbidity   0.022 
Yes 23 (52.3) 31 (32.0)  
No 21 (47.7) 66 (68.0)  
Other comorbidity   0.171 
Yes 24 (54.5) 40 (42.1)  
No 20 (45.5) 55 (57.9)  
Siblings   0.744 
0 10 (22.2) 24 (24.7)  
+1 35 (77.8) 73 (75.3)  
Housing   0.381 
Single family/duplex 9 (20.0) 26 (26.8)  
Multifamily (items 3-8) 36 (80.0) 71 (73.2)  
Vaccinated   0.210 
1+ doses vaccine 5 (11.1) 19 (19.6)  











  Other  comorbidities  include  sickle  cell  disease,  renal  disease,  heart  problems,  immune 






















   










Age at Hospitalization*   0.002 
> 2 years 14 (58.3) 101 (85.6)  
≤ 2 years 10 (41.7) 17 (14.4)  
Gender   0.295 
Female 10 (41.7) 63 (53.4)  
Male 14 (58.3) 55 (46.6)  
Race/Ethnicity   0.443 
White 16 (66.7) 75 (63.5)  
Black or other 5 (20.8) 15 (12.7)  
Hispanic 3 (12.5) 27 (22.8)  
Breastfed (self-reported)   0.920 
Yes 15 (62.5) 70 (61.4)  
No 9 (37.5) 44 (38.6)  
Caregiver education   0.709 
College graduate 13 (56.5) 58 (52.3)  
Some college or less 10 (43.5) 53 (47.7)  
Household income   0.412 
>$30K 15 (65.2) 53 (55.8)  
<$30K 8 (34.8) 42 (44.2)  
Preterm   0.052 
Yes 7 (29.2) 15 (13.2)  
No 17 (70.8) 99 (86.8)  
School/daycare attendance   0.113 
Yes 16 (66.7) 95 (81.2)  
No 8 (33.3) 22 (18.8)  
Respiratory comorbidity   0.930 
Yes 9 (37.5) 45 (38.5)  
No 15 (62.5) 72 (61.5)  
Other comorbidity   0.669 
Yes 12 (50.0) 52 (45.2)  
No 12 (50.0) 63 (54.8)  
Siblings   0.512 
0 7 (29.2) 27 (22.9)  
1+ 17 (70.8) 91 (77.1)  
Housing   0.109 
Single family/duplex 9 (37.5) 26 (22.0)  












  Other  comorbidities  include  sickle  cell  disease,  renal  disease,  heart  problems,  immune 








Matched conditional logistic regression 





















Multivariate Odds Ratio predicting likelihood to be hospitalized due to H1N1 












Adjusted Matched Multivariate Analysis with Odds Ratio of Vaccination status for H1N1 
















Hospitalization Diagnosis   0.374 
H1N1 influenza (case subject) 22 (33.3) 15 (27.8)  
Non-respiratory (control subject) 44 (41.7) 39 (72.2)  
   
Odds Ratio:  
0.695 
(0.645-3.218) 
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CHAPTER 4 
DISCUSSION 
 
Vaccination with one dose of unadjuvanted H1N1 vaccine was only 30.5% 
protective against hospitalization for H1N1 influenza‐related illness in our sample. 
Existing immunological research suggests there is an age‐related difference in the 
ability to mount a robust response to vaccine antigen required for effective 
immunization (34, 35, 48, 50), and that even older children and adolescents—
despite their more competent immune systems compared to younger children—
have lower baseline protection from cross‐reactive antibodies due to lack of 
exposure to previously circulating H1N1 subtype influenza viruses (1, 19, 40, 55). 
Effectiveness studies and long‐term immunogenicity studies that found an influenza 
vaccine effectiveness of >80% in young children and adolescents, or persistently 
elevated protective antibody titers, were conducted using vaccines with adjuvants 
(33, 41, 52), which are not licensed for flu vaccines in the United States (1, 36). 
Further, head‐to‐head studies of adjuvanted flu vaccines versus conventional 
vaccines have found markedly poorer results in the unadjuvanted vaccines in 
achieving a protective antibody titer (>1:40) (42). In 2011, The World Health 
Organization in its Seventh Meeting on Evaluation of Pandemic Influenza Vaccines in 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Clinical Trials explicitly stated that unadjuvanted vaccines and very‐low dose 
adjuvanted vaccines were not capable of eliciting reliable seroprotection in children 
(17). 
Adjuvanted vaccines have suffered a poor public relations image secondary to 
concerns that vaccine preservatives such as thimerosal and other additives 
including MF59 and AS03 adjuvants, lead to an increased risk of autism in children 
despite lack of scientific evidence to support this claim. It is possible that the strong 
lobbying efforts by anti‐vaccine groups involved in vaccinations has resulted in 
adjuvants not being embraced for influenza vaccines in the United States despite 
their proven value in producing highly effective vaccines. With every vaccine 
administration, there is a risk‐reward ratio – and adjuvants are perceived to 
contribute substantial risk without commensurate reward, when the evidence 
points to the opposite being true. In fact, safety studies have not thus far shown 
statistical differences in side effects or serious events in conventional versus 
adjuvanted vaccines (39, 43, 44) or in multiple doses of vaccine (38), rendering 
safety concerns about vaccine adjuvants without teeth.  
Since we found that one dose of unadjuvanted H1N1 influenza vaccine is not 
highly protective in young children, possible solutions include bolstering current 
recommendations for young children to receive a second dose (up to nine years old 
with certain preparations according to immunological research) (39), a higher 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initial dose of antigen (47), and/or introducing adjuvanted vaccines for influenza. 
These options taken together or separately could serve to reduce the toll on the 
healthcare system currently observed due to influenza related illnesses, as well as 
enable a better risk‐reward profile to vaccination.  Additionally, research shows that 
consumers of influenza vaccines, or in the case of pediatric patients, their parents, 
have diminished safety concerns with each subsequent vaccination, and they are 
overall more likely to be vaccinated subsequently once they have been initiated into 
receiving influenza vaccinations (49, 52).  
Other areas of improvement identified by our research include issues of 
disparity. Individuals of lower socioeconomic status and minority status are at 
greater risk of hospitalization from influenza, and should be priority targets for 
effective vaccination programs. Given the average savings to the healthcare 
apparatus of an average of $8‐52,000 per flu hospitalization prevented (26, 53), it 
would be a sound policy choice to subsidize influenza vaccines for individuals not 
able to afford them.  
It does appear that certain high‐risk patients are being targeted for 
immunization, as the younger children in our study were significantly more likely to 
be vaccinated than those over the age of two. Especially vulnerable groups such as 
children and adolescents with respiratory comorbidities including asthma were 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disproportionately hospitalized for influenza complications in our sample, and 
would receive particular benefit from effective prevention strategies.  
Our study did have some weaknesses. Although we computed a provisional vaccine 
efficacy based on our data, we were not powered to detect such a small protective 
effectiveness of the vaccine because we designed our study based on published data 
from previous influenza vaccines for seasonal influenza which are typically in excess 
of 80% effective in preventing influenza infection.  Therefore, with a larger sample 
size we might detect a different vaccine efficacy. Future research in partnership 
with the Connecticut Children’s Medical Center to combine sample sizes may further 
elucidate this issue, and will likely alter the protective efficacy of the vaccine in our 
sample. Since we were adequately powered to detect an 80% protective effect of the 
H1N1 vaccine in preventing hospitalization due to influenza in pediatric patients, 
we do know that it is <80% effective and that further study is warranted to help 
articulate vaccine policy and promote effective vaccine preparations and vaccine 
dosing regimens in order to encourage responsible and prudent use of preventative 
healthcare resources. 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